Active Ingredient History

  • Now
Preladenant was a drug that was developed by Schering-Plough which acted as a potent and selective antagonist at the adenosine A2A receptor. It was being researched as a potential treatment for Parkinson's disease. Positive results were reported in Phase II clinical trials in humans, but it did not prove itself to be more effective than a placebo during Phase III trials, and so was discontinued in May 2013.   Wikipedia

  • SMILES: COCCOc1ccc(cc1)N2CCN(CCn3ncc4c3nc(N)n5nc(nc45)c6occc6)CC2
  • Mol. Mass: 503.57
  • ALogP: 2.16
  • ChEMBL Molecule:
More Chemistry
2-(2-furanyl)-7-(2-(4-(4-(2-methoxyethoxy)phenyl)-1-piperazinyl)ethyl)-7h-pyrazolo(4,3-e)(1,2,4)triazolo(1,5-c)pyrimidine-5-amine | mk-3814 | preladenant | sch420814 | sch 420814 | sch-420814


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue